Item 2.02 Results of Operations and Financial Condition.
On
The preliminary unaudited cash position discussed above is subject to the
completion of financial closing procedures and other developments that may arise
between now and the time the financial results for the fourth quarter of 2022
are finalized, as well as the completion of the audit of the 2022 financial
statements. Therefore, actual results may differ materially from these
estimates. In addition, the above estimates do not present all information
necessary for an understanding of the Company's financial condition as of
The information contained in this Current Report on Form 8-K under Item 2.02 is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and will not be incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, unless specifically identified as being incorporated therein by reference.
Item 8.01 Other Events.
On
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. Exhibit Number Description 99.1 Presentation Materials ofKura Oncology, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source